Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

• Main Authors: Emily M. J. Fennell (Author), Lucas J. Aponte-Collazo (Author), Wimal Pathmasiri (Author), Blake R. Rushing (Author), Natalie K. Barker (Author), Megan C. Partridge (Author), Yuan-Yuan Li (Author), Cody A. White (Author), Yoshimi E. Greer (Author), Laura E. Herring (Author), Stanley Lipkowitz (Author), Susan C. J. Sumner (Author), Edwin J. Iwanowicz (Author), Lee M. Graves (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes f...